peptide hits

Plano-Based Orano Med to Collaborate with U.K. Company on Novel Cancer Therapies

by | Sep 12, 2023
“Since the inception of Orano Med, we've recognized the value of collaboration,” Orano Med CEO Julien Dodet said. “In our strategy to develop and deliver 212Pb Targeted Alpha Therapy for cancer patients, we’re delighted to work with Orbit Discovery and leverage its technology and expertise in peptide ligand discovery to build our pipeline of radiotherapies.”
MORE